SOPHIA ANTIPOLIS, France – November 21, 2025 │ October 21, 2025 – Takeda has entered into a license and collaboration agreement with Innovent Biologics for the development, manufacturing and commercialization of two late-stage oncology medicines, worldwide outside of Greater China. First, there is IBI363, a PD-1/IL-2α-bias bispecific antibody fusion protein, evaluated in non-small cell lung[…]
SOPHIA ANTIPOLIS, France – November 04, 2025 │ French biotechnology company Core Biogenesis has recently presented at Cosmetic 360, its oleosome-based growth factor platform promising anti-aging efficacy and supported by a sustainable and scientifically proven approach. Knowmade deciphers the science and the intellectual property behind the innovation. About Core Biogenesis Core Biogenesis is a biotechnology[…]
SOPHIA ANTIPOLIS, France – October 24, 2025 │ Hansoh Pharmaceutical has signed a license agreement with Roche to develop HS-20110, a CDH17-targeting antibody-drug conjugate (ADC) utilizing a clinically validated topoisomerase inhibitor payload. Hansoh Pharma gives Roche an exclusive worldwide license (excluding the Chinese Mainland, Hong Kong, Macau and Taiwan) to advance the clinical development and[…]
SOPHIA ANTIPOLIS, France – October 17, 2025 │ This quarter, KnowMade’s Therapeutic mRNA patent monitoring service reveals two emerging players shaping the next wave of RNA innovation: Parcel Bio, pioneering nanoparticle-free delivery, and ArkeaBio, developing mRNA vaccines for methane mitigation. Two Emerging Players Expand the Frontiers of Therapeutic mRNA Innovation Two new entrants have emerged[…]